Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial

Results reinforce commitment to next-generation oral SERD development programme

Laurus Labs planning Rs. 2,000 Cr Capex

On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions

RPG Life Sciences Q2 FY23 revenue up 20%; PBT up 21%

In Q2 FY23, the overall performance of the company continued to be strong despite the ongoing geo-political challenges impacting supply chain and costs

ICON selected by BARDA to conduct anthrax vaccine clinical trial

This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.

Piramal Pharma appoints Vibha Paul Rishi as Non- Executive Director

Japan homegrown COVID-19 mRNA vaccine needs superior safety and efficacy data for success, says GlobalData

The booster vaccination trial is still ongoing and further data will provide more information around safety and efficacy.

Bausch and Glenmark announce approval of RYALTRIS in Canada

RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray

KDAH receives SMART ICU certification after pandemic

Kokilaben Hospital is also the first hospital in Navi Mumbai to receive the SMART ICU certification

BridgeBio Pharma, Sentynl Therapeutics receive marketing authorization in the EU for fosdenopterin

NULIBRY is a first-in-class cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A.

Reasons for the surge in M& A in healthcare and pharmaceutical sectors in India: Ankit Poddar & Navroz Mahudawala, Candle Partners

Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.